Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms.
| Revenue (Most Recent Fiscal Year) | $167.13M |
| Net Income (Most Recent Fiscal Year) | $-4.03M |
| PE Ratio (Current Year Earnings Estimate) | 35.64 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 12.40 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.45 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 66.98 |
| Pre-Tax Margin (Trailing 12 Months) | 1.51% |
| Net Margin (Trailing 12 Months) | -2.41% |
| Return on Equity (Trailing 12 Months) | -0.81% |
| Return on Assets (Trailing 12 Months) | -0.72% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.93 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.55 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.63 |
| Book Value per Share (Most Recent Fiscal Quarter) | $43.95 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.64 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.22 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.16 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 19.25M |
| Free Float | 18.12M |
| Market Capitalization | $2.07B |
| Average Volume (Last 20 Days) | 0.14M |
| Beta (Past 60 Months) | 1.12 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 91.28% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |